SCHEMBL3247153

SCHEMBL3247153

Cc1[c]ccc(CNc2cccc(F)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.51
MAPT P10636 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NOS1 P29475 1/20 0.48
ALDH1A1 P00352 2/20 0.45
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45
ALOX15 P16050 1/20 0.45
ALOX12 P18054 1/20 0.45
HSD17B10 Q99714 1/20 0.45
HDAC4 P56524 1/20 0.44
MEF2D Q14814 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
SLC2A1 P11166 1/20 0.42
HDAC1 Q13547 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14672469 0.83 AURKA (0.43) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL3248749 0.82 HPGD (0.51) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL6229701 0.79 HPGD (0.65) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL10055035 0.77 HPGD (0.67) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL3247409 0.76 HPGD (0.45) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL3251941 0.76 KMT2A (0.43) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL6696141 0.76 HPGD (0.60) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL4951737 0.75 MAPT (0.59) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL11015099 0.74 HPGD (0.63) HPGDMAPTMEN1KMT2ANOS1
SCHEMBL3246732 0.73 FFAR1 (0.45) MAPTFFAR1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP claimed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO claimed